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Abstract
This study investigated the current ethical issues in relation to recognizing and managing Parkinson disease (PD) from the
patient’s perspective. Methods: Twelve patients living with PD who were from the medical school’s Patients as Educators
program were recruited. Semistructured interviews were conducted to record patient experiences in order to identify
potential ethical issues in relation to recognizing and managing PD. Thematic analysis was applied to the interview transcripts.
Results: Four key themes emerged from the interviews. These were information giving, coping, identity, and future medical
treatment. These data indicate variable experiences in relation to communication between patient and health-care profes-
sional, better support for both planning end-of-life decisions and in coping with the disease’s impacts on their identity. Patients
with PD also struggle with access to support services and support for main carer. Implications: To ensure ethical practice in
supporting patients with PD, these emerging themes need further investigation; and management guidelines relevant to PD
must be informed by research in this area to ensure ethical care of patients with PD, their carers, and families.
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Approximately 1 in 500 people in the United Kingdom are
currently affected by Parkinson disease (PD; 1), and it is
estimated that by 2030, the number of individuals with PD
worldwide will be in the region of 9 million (2). Medical
professionals are faced with many ethical challenges when
treating a patient with PD because of the diverse presentation
of symptoms over time and the late onset complication of
dementia affecting older patients with prolonged disease
duration (3). In addition to complications relating to demen-
tia, progression of PD significantly impacts on the mental
well-being of the patients, requiring sociopsychological
issues to be considered in the long-term management of the
patients (4,5). These inherent complexities point toward
potential ethical considerations in ensuring best practice in
caring for patients diagnosed with PD and their families.
However, the recent literature largely focuses on non–data-
driven analyses and novel therapies instead of issues related
to practical day-to-day care (6). Little focus is given in the
recent literature to the everyday ethical challenges and con-
cerns from the point of view of the patient. In this article, we
investigate the current ethical issues in relation to recogniz-
ing and managing PD from the patients’ perspective.
Methods
A literature review was firstly undertaken to investigate cur-
rent ethical issues in PD. Conclusions from the literature
review informed the structure of a semistructured interview
to explore the ethical issues from the patients’ perspective.
Semistructured interviews with participants of the Patients as
Educators (PAE) program who have a diagnosis of PD was
then undertaken. The interview was composed of 4 standar-
dized open-ended questions allowing the interviewee to
reflect and detail their experiences in their own words (see
Box 1 for the key questions employed in the interview). The
exact wording and sequence of questions were determined in
advance. The strength of this process was that it increased
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the comparability of responses with complete data for each
participant. It reduced interviewer effects and bias (7). These
interviews were transcribed and analyzed thematically.
Participant Characteristics
The PAE database consisted of 763 patients at the time of
data collection; of these, 24 patients had a diagnosis of PD.
Patients were invited from the list for interviews on prede-
termined days when the lead author had availability. The
only criterion for invitation was a diagnosis of PD. All
invited patients consented to be interviewed. Of the 12 PAEs
interviewed, 5 were female (their ages ranged from 51-70)
and 7 male whose ages ranged from 60 to 86. The length of
time since their diagnosis ranged from 11 months to 24
years. Four participants were of working age but were unable
to work because of their PD, and 8 participants were retired.
All participants lived with a partner, who was their carer,
apart from 1 participant who lived alone.
The number of participants to interviewwas not established
ahead of time. The data collection was continued until satura-
tion of themes was reached and no new information emerged
from the data. The semistructured interviews were audio
recorded and transcribed. These data were then analyzed to
look for patterns of meaning and topics of potential interest.
Next came the production of codes, which aimed to organize
the data into meaningful groups to indicate potential themes. It
was attempted to code for asmany potential themes as possible
in order to ensure that the context of the data was not lost (8).
Once coding was completed, the search for themes began. The
codes were analyzed and a thematic map was produced to help
sort the codes into themes and subthemes. The themes were
then checked against the data to ensure that they accurately
reflected themeanings evident in the transcripts. Thiswas done
to ensure a rigorousmethod of analysis had been undertaken in
order to provide merit and validity to the findings.
Discussion of the Key Themes From
the Interviews
Four key themes emerged: information giving, coping, iden-
tity, and future medical treatment. Each theme contained
subthemes, and the findings are supported by extracts from
the transcripts to demonstrate that themes were grounded in
the data. The results are organized in Tables 1 to 4 by the 4
main themes.
Theme 1: Information Giving
This theme had 3 subthemes of perceptions about
“diagnosis as closure,” “varying experience of how the
diagnosis was given” and whether “the level of information
helped with coping.”
Most interviewees stated they felt better after full disclo-
sure of their diagnosis. This was because in many cases, a
delayed diagnosis had often been a cause for concern due to
on-going unexplained physical symptoms and negative test
results. Once patients were diagnosed with PD they accepted
this, getting closure (Table 1: quotes 1–3). Several intervie-
wees were satisfied with the way in which they were given
their PD diagnosis whereas others had a negative experience
such as being informed of their diagnosis in a nonprivate
setting. This is against good practice in breaking bad news
(9). Another patient felt the clinician was abrupt and imper-
sonal when giving the PD diagnosis. This may be due to
clinicians feeling guilty about not being able to offer a valid
solution, which affects perceived appropriate timing and
manner of disclosure (10) (Table 1: quote 4). Several
Table 1. Theme 1: Information Giving.
Theme 1: Information
Giving
Quotes
No. Quotes From Patients
Diagnosis as closure 1. “I knew something had been going
on for a while . . .when I got the
diagnosis I felt a bit better”
2. “It took 6 years from start to
finish to actually get a diagnosis. I
had a lot of different health
problems”
3. “A young doctor saw me and said
— how long have you had PD? I
had a shake and I think he saw the
stare. I was referred to a
neurologist. They confirmed the
diagnosis. It was a shock, but a
relief that it was something that
could be dealt with”
Experience of being
given the diagnosis
4. “There were 2 medical students
in the room but he didn’t
introduce them before he told
me. I would have preferred to be
more private. It was a bombshell”
Information helped/
hindered ability to
cope
5. “I had an interview with the PD
nurse. She gave me all the
information about PD and I felt
OK at that stage”
6. “The nurses left me with lots of
leaflets and I made the mistake of
reading every one of them. I felt
worse after my diagnosis and was
devastated at first”
1. Who gave you your diagnosis and when did you
receive this information?
2. Is the treatment you are receiving effective?
3. How has life changed and what are the challenges
of living with your condition?
4. What plans have you made regarding your wishes
for future medical treatment?
Box 1. Interview Questions.
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interviewees’ felt that receiving as much information as pos-
sible helped them to cope with their diagnosis. Others felt
that they were given too much information and this hindered
their ability to cope with the devastating news (Table 1:
quotes 5,6).
Theme 2: Coping with PD
There were several factors/subthemes that encompassed
coping and included medication management, support from
health-care professional or family, poor access to health-care
professionals, and impact of relationships within the team on
the patient.
Compulsive behavior (gambling) and frightening night-
mares occurred in 2 patients as a side effect of their PD
medication. Both patients were eventually offered alterna-
tive medications and the problems stopped (Table 2: quotes
4–5).
The patients were prescribed 7 different PD medications
overall, and it appears that most prescriptions were altered
over time in order to find the right drug and dosage for each
individual. The principle of beneficence appears to be work-
ing well here with these efforts being an indication to
improve efficacy of prescribed medication. However, there
is currently limited evidence exploring the interindividual
differences in response to drug treatment (11,12). One
patient, who before receiving deep brain stimulation (DBS)
had suffered severe physical symptoms, was adapting well to
the stimulator (Table 2: quote 6). This was despite the need
for continuous device activity that sometimes causes feel-
ings of strangeness or change in identity (13). All patients
who regularly saw a PD nurse held them in high regard and
felt them to be caring and supportive (Table 2: quote 7).
Several interviewees felt that a lack of interdisciplinary
cooperation between health professionals led to unwarranted
challenges to their care (Table 2: quotes 10,13). Most inter-
viewees had a spouse who was also their carer. Some were
elderly with health problems of their own. This was a source
of worry for several patients who felt their spouses got little
support (Table 2: quote 9).
Theme 3: Identity
These data suggest that the disease impacted on self-identity
through “self-esteem,” “limit to independence” and
“compromises in relationships.”
Several interviewees felt that physical changes due to PD
had changed their identity and they experienced low self-
esteem or “worthlessness.” (Table 3: quotes 1–3). Loss of
independence was a major challenge for the interviewees. For
example, most interviewees had made up their own minds to
stop driving and they appeared to be aware they should no
longer be on the road (Table 3: quote 5). This shows that when
possible it is appropriate to let patients lead on such decision-
making. All interviewees reported regular appointments with
their General Practitioner (GP), PD nurse, and neurologist, but
not access to the multi-disciplinary team (MDT) that is recom-
mended for maintaining Quality of Life (QOL) (14).
Table 2. Theme 2: Coping.
Theme 2: Coping Area of Focus
Quotes
No. Quotes From Patients
Medication
management
Medication 1. “The medication has only recently started working. It’s taken a long time to get the
dosage right. I am now more myself”
2. “I take medication every 4 hours. It is effective. Without it I would not get out of
bed”
3. “It’s horrendous (the medication). Made me feel worse. I worked on a switchboard
then and I fell”
4. “It made me start gambling. I got into it really bad and I never had any addictions
before”
5. “I had terrible nightmares before the patches, and hallucinations. I still have those, I
see things going past me”
DBS 6. “Since the DBS, the stiffness and tremor have been better. I feel well. I have now
halved the medication. My family are amazed and it has made a big difference”
Support From a health
professional
7. “The PD nurse has been lovely and helped me to cope”
From partner/family 8. “I and my wife are a team, getting on with it. She does a lot for me, simple things”
9. “She is 74, she has health problems. I leave her in bed for as long as I can”
Access Lack of access to
medical profession
10. “I cannot get a repeat prescription automatically and I need to see the doctor.
Controversial as I can’t get in to see the doctor”
Falls 11. “Not allowed to be left alone, no independence. She is frightened of me falling
because my biggest fear is falling”
Impact of intra
team relationships
Interdisciplinary
relationships
12. “The GP refers to the neurologist and then the GP always rings me back”
13. “The diabetic nurse says she would like to change things but the consultant says no,
leave it as it is”
Shaw and Vivekananda-Schmidt 3
Theme 4: Future Medical Treatment
This theme comprised of challenges in planning for “end of
life” and “treatment choices” in the future.
Few interviewees had considered that at some stage they
may develop cognitive dysfunction and most had not made
any provision for this outcome (Table 4: quotes 1,3). Parkin-
son disease can leave patients unable to make legally binding
decisions about future medical treatment, highlighting the
importance of advance planning. Several interviewees had
already prepared advance directives but most had never dis-
cussed this with anyone (Table 4: quotes 1,3). One patient
who had made an advance directive did so as a result of
mistaken views about the Liverpool Care Pathway propa-
gated by the media (Table 4: quote 2). Another patient dis-
cussed “going to Switzerland when the time is right”
showing an understanding of current UK law. Patients and
families need to be well informed to make good decisions
about future care, and when a patient lacks capacity, family
has input in the decision-making process (Table 4: quote 1).
The issue of inadequate End of Life (EOL) discussions
raised by the participants here should be further explored
to understand the prevalence and nature of the issues in a
larger population. Several interviewees had been given
information about DBS as a possible future treatment but
were not ready to consider this procedure (Table 4: quote
4). They felt they were either too young or not yet at an
advanced stage of the disease. The patients have a right to
refuse DBS surgery, which should be respected, even if the
decision is not in their best interests.
The literature indicates, patients do prefer full disclosure
when given a diagnosis of a neurological condition in the
early stages of their disease; this helps them to understand
the condition and what the future might hold (15). Older
patients sought less detailed information and preferred less
involvement in treatment decisions (16). When disclosing a
neurological diagnosis, clinicians only tend to address the
physical consequences of the disease, suggesting that clin-
icians might not want to burden the patient with the knowl-
edge of possible psychological symptoms (17). These
findings were supported by data collected from patients with
PD (see Table 3). However, clinicians did aim to establish a
good physician–patient relationship over time (10).
Ethical challenges to QOL when living with a neurological
condition were discussed in the literature, in particular with
regard to medication and its potential side effects. It is recog-
nized that medication in patients with PD should be reviewed
regularly and discontinued if causing behavioral dysfunction
(18). This is supported by our data (Table 2: quotes 1, 3).
Clinicians should discuss potential life-changing decisions,
such as giving up driving, with patient and family in order to
avoid potential problems (18); patients with PD should be
treated by a MDT to optimize QOL (14). However, lack of
expertise among health professionals, little interdisciplinary
cooperation, and decreased financial support are all barriers to
successful MDT care (19). It is also important to treat patient
and carer as a “unit,” with the QOL of the carer linked to the
physical and mental health of their charge (20). In relation to
making advance plans for future medical treatment, it was
found that health professionals felt it was of high importance
to understand and implement the future wishes of their neu-
rological patients (21). Perhaps, the unpredictability of neu-
rodegenerative disease makes palliative care plans difficult
and this may be a reason why discussions about EOL do not
always take place. With the exception of 1 paper (22), we
were unable to find literature that addresses how to help
patients with PD cope with conflicts in their identity due to
impact of the disease; this was the same with regard to sup-
porting patients with PD about EOL issues indicating the need
for further work in these areas.
Strengths and Limitations of the Data
This study provides an insight into the current ethical chal-
lenges related to supporting patients with PD. Information
was gathered relating to how patients with PD receive their
diagnosis, the ongoing QOL challenges the patients face and
how they cope with day-to-day living, loss of identity, and
their relationships with others. It also reflects on how patients
with PD feel about their future. The findings show that key
issues center on disclosure, pharmaceutical and
Table 3. Theme 3: Identity.
Theme 3 :
Identity
Quotes
No. Quotes From Patients
Self esteem 1. “I really felt that my self-esteem went
down . . . sometimes people stare,
children are difficult. It was really
tempting to hide myself away but I had
to get on with my life, it’s like punishing
yourself otherwise”
2. “Biggest challenge, my feelings, trying to
have value. It takes so long to do
anything”
3. “I can’t do things around the house as
my fingers don’t work properly and then
I get frustrated. The biggest challenge is
realizing I can’t do what I took for
granted”
Independence 4. “The biggest challenge is that I can’t go
to town on my own. I have lost my
independence”
5. “I decided to give up driving. Every time
I went out I would be driving along the
street and I would hit the kerb”
6. “I can’t work now, had that many stays
in hospital. My wife had to give up work
as I was in and out of hospital, the bills
were mounting and my oldest son is
autistic”
Compromised
relationships
7. “My husband has got quite snappy, tells
me to stop shuffling my feet. He finds it
stressful. He tells me to speak up all the
time”
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nonpharmaceutical treatment, and involving patients in EOL
decisions. However, the interviewees are selected from 1 sin-
gle site and chosen “conveniently” because they had PD (23)
and were part of the PAE program at the medical school. It is
important to consider how and whether PAEs differ from
other patients with PD. The data collection was limited to
patients and did not include clinicians and other stakeholders,
preventing the opportunity to obtain a multistakeholder view.
Implications for Future Research and Practice
In many areas, this small data set indicate mixed messages;
for example, about satisfaction with receiving diagnosis,
support with regard to future medical care or with end-of-
life care planning. These maybe indicative of variable qual-
ity of experiences. To ensure that management of patients is
ethical, equity in patients’ experiences is important. Future
research therefore needs to explore the issues emerging in
this interview study further, both from patient as well as
carer and the medical team’s perspectives.
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